<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349388</url>
  </required_header>
  <id_info>
    <org_study_id>R05-11-010</org_study_id>
    <nct_id>NCT00349388</nct_id>
  </id_info>
  <brief_title>Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients</brief_title>
  <official_title>A Randomized Trial Comparing Once Daily Dosing vs. Multiple Doses a Day of Mesalamine in Pediatric Patients With Quiescent Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annette Langseder</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atlantic Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether once a day administration of Mesalamine is at least as safe and
      efficacious and administration of multiple doses a day in preventing clinical relapse of
      ulcerative colitis in children and adolescence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Is taking total dose in mg/kg once a day, as safe as taking total dose divided in mg/kg
      spreadout during the day in preventing clinical relapse of ulcerative colitis in children and
      adolescence.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    none enrolled in second arm, therfore no analysis
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Once Daily Dosing Works as Well a Multiple Dosing a Day.</measure>
    <time_frame>overall study</time_frame>
    <description>subject tolerated once a day dose Only 1 subject enrolled which was the control arm standard dose twice a day. No subjects enrolled to take dose once a day Therefore, primary outcome cannot be reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved Medication Compliance.</measure>
    <time_frame>overall study</time_frame>
    <description>unable to measure since no one enrolled in second arm. Therefore, no comparisons can be made.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Asacol once a day dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asacol total dose in mg/kg given once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asacol BID/TID dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Asacol total dose split BID or TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asacol</intervention_name>
    <description>Asacol is given once a day versus twice or three times a day</description>
    <arm_group_label>Asacol once a day dosing</arm_group_label>
    <arm_group_label>Asacol BID/TID dosing</arm_group_label>
    <other_name>Mesallamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 6 to 18 years,

          -  Must be able to swallow tablets, and

          -  Biopsy proven ulcerative colitis

        Exclusion Criteria:

          -  Allergy or hypersensitivity to Mesalamine or other salicylates

          -  Use of rectal medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Rosh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlantic Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Morristown Memorial Hospital/Goyerb Children's Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2006</study_first_posted>
  <results_first_submitted>July 24, 2014</results_first_submitted>
  <results_first_submitted_qc>August 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2014</results_first_posted>
  <last_update_submitted>August 13, 2014</last_update_submitted>
  <last_update_submitted_qc>August 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Atlantic Health System</investigator_affiliation>
    <investigator_full_name>Annette Langseder</investigator_full_name>
    <investigator_title>Joel Rosh, MD</investigator_title>
  </responsible_party>
  <keyword>Mesalamine</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Asacol Once a Day Dosing</title>
          <description>Asacol total dose in mg/kg given once a day
Asacol: Asacol is given once a day versus twice or three times a day</description>
        </group>
        <group group_id="P2">
          <title>Asacol BID/TID Dosing</title>
          <description>Asacol total dose split BID or TID
Asacol: Asacol is given once a day versus twice or three times a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">no patients enrolled</participants>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">no patients enrolled , therefore no patients completed</participants>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No patients enrolled into intervention arm due to lack of enrollment.Only 1 subject was enrolled in Control arm. Therefore no data can be compared for study outcome</population>
      <group_list>
        <group group_id="B1">
          <title>Asacol Once a Day Dosing</title>
          <description>Asacol total dose in mg/kg given once a day
Asacol: Asacol is given once a day versus twice or three times a day</description>
        </group>
        <group group_id="B2">
          <title>Asacol BID/TID Dosing</title>
          <description>Asacol total dose split BID or TID
Asacol: Asacol is given once a day versus twice or three times a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Once Daily Dosing Works as Well a Multiple Dosing a Day.</title>
        <description>subject tolerated once a day dose Only 1 subject enrolled which was the control arm standard dose twice a day. No subjects enrolled to take dose once a day Therefore, primary outcome cannot be reported</description>
        <time_frame>overall study</time_frame>
        <population>cannot analysze primary outcome because no subjects were enrolled in the once a day dose arm. Study was terminated due to lack of enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Asacol Once a Day Dosing</title>
            <description>Asacol total dose in mg/kg given once a day
Asacol: Asacol is given once a day versus twice or three times a day</description>
          </group>
          <group group_id="O2">
            <title>Asacol BID/TID Dosing</title>
            <description>Asacol total dose split BID or TID
Asacol: Asacol is given once a day versus twice or three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Once Daily Dosing Works as Well a Multiple Dosing a Day.</title>
          <description>subject tolerated once a day dose Only 1 subject enrolled which was the control arm standard dose twice a day. No subjects enrolled to take dose once a day Therefore, primary outcome cannot be reported</description>
          <population>cannot analysze primary outcome because no subjects were enrolled in the once a day dose arm. Study was terminated due to lack of enrollment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improved Medication Compliance.</title>
        <description>unable to measure since no one enrolled in second arm. Therefore, no comparisons can be made.</description>
        <time_frame>overall study</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>180 days total</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Asacol Once a Day Dosing</title>
          <description>Asacol total dose in mg/kg given once a day
Asacol: Asacol is given once a day versus twice or three times a day</description>
        </group>
        <group group_id="E2">
          <title>Asacol BID/TID Dosing</title>
          <description>Asacol total dose split BID or TID
Asacol: Asacol is given once a day versus twice or three times a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No subjects were analysed due to lack of enrollment. No subject was enrolled into the once a day dosing arm to answer our primary or secondary outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Joel Rosh</name_or_title>
      <organization>Atlantic Health System</organization>
      <phone>973-971-5676</phone>
      <email>joel.rosh@atlantichealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

